Key result
Low ANGPTL4 expression in triple-negative breast cancer predicts ~100% worse disease-free survival versus high expression.
Why the study?
Triple-negative breast cancer patients have relatively poor outcomes, and markers predicting prognosis to help guide treatment are needed.
Does high ANGPTL4 expression predict improved survival in patients with triple-negative breast cancer?
Population
Patients with TNBC and TNBC cell lines
Comparison
ANGPTL4 expression levels
Design
Retrospective observational cohort and in vitro study
Authors
Loading...
High ANGPTL4 expression may signal better TNBC prognosis; leaves open its role in guiding therapy.
Cohort (n=161)
No
Does high ANGPTL4 expression predict improved survival in patients with triple-negative breast cancer?
Hazard Ratio: 2.005 (95% CI 1.121–3.585)
Absolute Event Rate: 56% vs 77%
p-value: p=0.019
ANGPTL4 overexpression is associated with favorable outcomes in TNBC patients and inhibits tumor cell adhesion and migration in vitro.
Cai et al. (2020) conducted a cohort in Triple-negative breast cancer (TNBC) (n=161). Low ANGPTL4 expression vs. High ANGPTL4 expression was evaluated on Disease-free survival (HR 2.005, 95% CI 1.121-3.585, p=0.019). Low ANGPTL4 expression in triple-negative breast cancer independently predicted shorter disease-free survival (HR 2.005) compared to high expression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: